Literature DB >> 12210878

Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.

Marcelo Merello1, Maria I Nouzeilles, Gabriel Piran Arce, Ramón Leiguarda.   

Abstract

Clinical idiopathic Parkinson's disease (PD) diagnosis requires following strict clinical criteria. Final definitive diagnosis can only be made after pathological confirmation and, despite following clinical criteria, several cases are misdiagnosed. We assessed sensitivity and specificity of acute challenge with levodopa (L-dopa) to predict sustained long-term L-dopa responsiveness as a major criterion for clinical diagnosis of PD. A consecutive series of 82 patients first seen at a movement disorders clinic with a parkinsonian syndrome without specific diagnosis was included. A second examiner, blind to the presumptive diagnosis, performed in each patient an acute challenge with 250/50 mg of L-dopa-carbidopa and rated the test as positive or negative according to whether values reached a minimal 30% of improvement on UPDRS scores. Positive tests were considered supportive of presumptive clinical diagnosis of Parkinson's disease. Blind to test results and according to clinical presumption, the first examiner started patient treatment with the necessary L-dopa dose or, alternatively, until reaching 1 g for 1 month in those who failed to display a positive test response. At 24 month follow-up, they were re-tested with 1 g for 1 month when required. At this point, clinical criteria of the U.K. Parkinson's Disease Society Brain Bank were applied and definitive clinical diagnosis of PD was made. Sensitivity, specificity, and positive predictive ratio for acute challenge were calculated. Overall sensitivity and specificity of acute L-dopa challenge to predict clinical diagnosis of PD was 70.9% and 81.4%, respectively; positive predictive ratio was 88.6%. When patients were divided into three groups according to their UPDRS motor section score at initial examination, sensitivity and specificity varied: Group I (<or= 10), 71.4% and 100%; Group II (11-20), 75% and 75%; and Group III (>or=21), 36.4% and 87%, respectively. Positive predictive ratio increased to 100% in Group I and to 87.5% in Group III. The positive result of initial acute L-dopa challenge predicts chronic L-dopa responsiveness as major criterion of PD in all patients with UPDRS motor scores lower than 10. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210878     DOI: 10.1002/mds.10123

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

1.  Facial tremors in patients with and without parkinsonism.

Authors:  Malco Rossi; Miguel Wilken; Pierre Morisset; Sofia Fariña; Daniel Cerquetti; Marcelo Merello
Journal:  Neurol Sci       Date:  2016-07-28       Impact factor: 3.307

2.  The role of levodopa in the management of dementia with Lewy bodies.

Authors:  S Molloy; I G McKeith; J T O'Brien; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

Review 3.  INPH and Parkinson disease: differentiation by levodopa response.

Authors:  Takashi Morishita; Kelly D Foote; Michael S Okun
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

4.  Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans.

Authors:  Joong-Seok Kim; Yeong-In Kim; Christopher Song; Injin Yoon; Jeong-Wook Park; Young-Bin Choi; Hee-Tae Kim; Kwang-Soo Lee
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

5.  Gait Analysis of Old Individuals with Mild Parkinsonian Signs and Those Individuals' Gait Performance Benefits Little from Levodopa.

Authors:  Zhuang Wu; Hang Xu; Sha Zhu; Ruxin Gu; Min Zhong; Xu Jiang; Bo Shen; Jun Zhu; Yang Pan; Jingde Dong; Jun Yan; Wenbin Zhang; Li Zhang
Journal:  Risk Manag Healthc Policy       Date:  2021-03-15

6.  Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.

Authors:  Manuela Contin; Giovanna Lopane; Pietro Cortelli; Luisa Sambati; Susan Mohamed; Giovanna Calandra-Buonaura
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

7.  Parkinson's disease.

Authors:  Madhuri Behari; Kalyan Brata Bhattacharyya; Rupam Borgohain; Shyamal Kumar Das; Bhaskar Ghosh; Asha Kishore; Syam Krishnan; K Rukmini Mridula; Uday Muthane; Pramod Kumar Pal; Charulata Sankhla; Garima Shukla
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

8.  Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus.

Authors:  Massimiliano Todisco; Roberta Zangaglia; Brigida Minafra; Patrizia Pisano; Giuseppe Trifirò; Irene Bossert; Nicoló Gabriele Pozzi; Joachim Brumberg; Roberto Ceravolo; Ioannis Ugo Isaias; Alfonso Fasano; Claudio Pacchetti
Journal:  Neurology       Date:  2021-04-23       Impact factor: 11.800

9.  Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa Cohort.

Authors:  Sebastian Schade; Friederike Sixel-Döring; Jens Ebentheuer; Xenia Schulz; Claudia Trenkwalder; Brit Mollenhauer
Journal:  Mov Disord Clin Pract       Date:  2017-06-30

10.  Diagnostic Value of Combined Acute Levodopa Challenge and Olfactory Testing to Predict Parkinson's Disease.

Authors:  Cinthia Terroba Chambi; Malco Rossi; Andrea Bril; Patricio Millar Vernetti; Daniel Cerquetti; Angel Cammarota; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2017-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.